TRIAL RESULTS · SIDE EFFECTS
Cagrilintide side effects
ANSWER
In 1 placebo-controlled trial with posted results, the most common side effects of Cagrilintide were nausea 29.0% (placebo 14.8%), COVID-19 16.1% (placebo 13.1%), constipation 16.1% (placebo 13.1%). Read from ClinicalTrials.gov on 2026-10-03. Not medical advice.
Trial register
Trials with posted results
1
with an arm on Cagrilintide, of 66 registered
Against placebo
1
placebo-controlled trials
People in those trials
31
on Cagrilintide · 61 on placebo
Read
2026-10-03
ClinicalTrials.gov
VS PLACEBO
Most common side effects, Cagrilintide beside placebo
Share of people with each side effect in 1 placebo-controlled trial with posted results: 31 people on Cagrilintide (all doses), 61 on placebo, same trials. Listed only when reported for at least half of the people on Cagrilintide. Source: ClinicalTrials.gov, read 2026-10-03. Not medical advice.
ALL TRIALS
All 35 side effects reported
Every trial with posted results and an arm on Cagrilintide (n ≥ 20), all phases, by people affected. Placebo is shown where placebo-controlled trials reported the same event. Comparator arms are not counted.
| Side effect | Organ system | Cagrilintide | Placebo | Trials |
|---|---|---|---|---|
| Nausea | Gastrointestinal disorders | 29.0% (9 of 31) | 14.8% | 1 |
| COVID-19 | Infections and infestations | 16.1% (5 of 31) | 13.1% | 1 |
| Constipation | Gastrointestinal disorders | 16.1% (5 of 31) | 13.1% | 1 |
| Diarrhoea | Gastrointestinal disorders | 16.1% (5 of 31) | 6.6% | 1 |
| Fatigue | General disorders | 9.7% (3 of 31) | 1.6% | 1 |
| Gastrooesophageal reflux disease | Gastrointestinal disorders | 9.7% (3 of 31) | 1.6% | 1 |
| Vomiting | Gastrointestinal disorders | 9.7% (3 of 31) | 1.6% | 1 |
| Back pain | Musculoskeletal and connective tissue disorders | 6.5% (2 of 31) | 3.3% | 1 |
| Eructation | Gastrointestinal disorders | 6.5% (2 of 31) | 0.0% | 1 |
| Gastroenteritis | Infections and infestations | 6.5% (2 of 31) | 6.6% | 1 |
| Hiccups | Respiratory, thoracic and mediastinal disorders | 6.5% (2 of 31) | 0.0% | 1 |
| Sinusitis | Infections and infestations | 6.5% (2 of 31) | 0.0% | 1 |
| Upper respiratory tract infection | Infections and infestations | 6.5% (2 of 31) | 8.2% | 1 |
| Arthralgia | Musculoskeletal and connective tissue disorders | 3.2% (1 of 31) | 4.9% | 1 |
| Dizziness | Nervous system disorders | 3.2% (1 of 31) | 6.6% | 1 |
| Injection site reaction | General disorders | 3.2% (1 of 31) | 3.3% | 1 |
| Acute sinusitis | Infections and infestations | 0.0% (0 of 31) | 3.3% | 1 |
| Blood creatine phosphokinase increased | Investigations | 0.0% (0 of 31) | 3.3% | 1 |
| Conjunctivitis | Infections and infestations | 0.0% (0 of 31) | 4.9% | 1 |
| Cough | Respiratory, thoracic and mediastinal disorders | 0.0% (0 of 31) | 3.3% | 1 |
| Decreased appetite | Metabolism and nutrition disorders | 0.0% (0 of 31) | 4.9% | 1 |
| Diabetes mellitus | Metabolism and nutrition disorders | 0.0% (0 of 31) | 3.3% | 1 |
| Dyspepsia | Gastrointestinal disorders | 0.0% (0 of 31) | 3.3% | 1 |
| Fall | Injury, poisoning and procedural complications | 0.0% (0 of 31) | 3.3% | 1 |
| Headache | Nervous system disorders | 0.0% (0 of 31) | 9.8% | 1 |
| Nephrolithiasis | Renal and urinary disorders | 0.0% (0 of 31) | 4.9% | 1 |
| Pain in extremity | Musculoskeletal and connective tissue disorders | 0.0% (0 of 31) | 3.3% | 1 |
| Urinary tract infection | Infections and infestations | 0.0% (0 of 31) | 4.9% | 1 |
| Acute myocardial infarction | Cardiac disorders | 0.0% (0 of 31) | 1.6% | 1 |
| Chest pain | General disorders | 0.0% (0 of 31) | 1.6% | 1 |
| Coronary artery disease | Cardiac disorders | 0.0% (0 of 31) | 1.6% | 1 |
| Deep vein thrombosis | Vascular disorders | 0.0% (0 of 31) | 1.6% | 1 |
| Hypotension | Vascular disorders | 0.0% (0 of 31) | 1.6% | 1 |
| Loss of consciousness | Nervous system disorders | 0.0% (0 of 31) | 1.6% | 1 |
| Pulmonary embolism | Respiratory, thoracic and mediastinal disorders | 0.0% (0 of 31) | 1.6% | 1 |
Source: ClinicalTrials.gov posted results, read 2026-10-03. A trial lists events above its own reporting threshold, so a rare event may be missing from some trials. Not medical advice.
QUESTIONS
Does cagrilintide cause nausea?
In 1 placebo-controlled trial with posted results, 29.0% of people on cagrilintide reported nausea, against 14.8% on placebo. Source: ClinicalTrials.gov, read 2026-10-03. Not medical advice.
Does cagrilintide cause COVID-19?
In 1 placebo-controlled trial with posted results, 16.1% of people on cagrilintide reported COVID-19, against 13.1% on placebo. Source: ClinicalTrials.gov, read 2026-10-03. Not medical advice.
Does cagrilintide cause constipation?
In 1 placebo-controlled trial with posted results, 16.1% of people on cagrilintide reported constipation, against 13.1% on placebo. Source: ClinicalTrials.gov, read 2026-10-03. Not medical advice.
Does cagrilintide cause diarrhoea?
In 1 placebo-controlled trial with posted results, 16.1% of people on cagrilintide reported diarrhoea, against 6.6% on placebo. Source: ClinicalTrials.gov, read 2026-10-03. Not medical advice.
Does cagrilintide cause fatigue?
In 1 placebo-controlled trial with posted results, 9.7% of people on cagrilintide reported fatigue, against 1.6% on placebo. Source: ClinicalTrials.gov, read 2026-10-03. Not medical advice.
REGISTERED STUDIES
66 registered clinical trials of Cagrilintide
The 10 most recently updated are listed.
| 2025-524249-29-00 | A placebo-controlled comparability study to compare two presentations of cagrilintide for weight management in participants with overweight or obesity Status: UNKNOWN · Updated 2026-10-01 |
|---|---|
| NCT05567796 | A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight Status: ACTIVE_NOT_RECRUITING · Updated 2026-09-30 |
| NCT06323174 | A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise Status: COMPLETED · Updated 2026-09-30 |
| NCT07011667 | A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term Status: ACTIVE_NOT_RECRUITING · Updated 2026-09-30 |
| NCT07253285 | A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight Status: RECRUITING · Updated 2026-09-30 |
| NCT07564414 | A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight Status: RECRUITING · Updated 2026-09-30 |
| NCT06131372 | A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo Status: COMPLETED · Updated 2026-09-24 |
| 2025-521384-12-00 | A research study to compare blood levels of cagrilintide after multiple doses of
different versions of cagrilintide in adults with overweight or obesity Status: UNKNOWN · Updated 2026-09-21 |
| NCT06797869 | A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy Status: COMPLETED · Updated 2026-09-10 |
| NCT07010432 | The Role of the Amylin Analogue Cagrilintide in Bone Metabolism Status: RECRUITING · Updated 2026-09-10 |
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.